ArticleFrontiers in immunology2025
Complete response and HBsAg clearance of advanced hepatocellular carcinoma associated with hepatitis B by DEB-TACE combined systematic therapy: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic therapy is the standard treatment for patients with hepatitis B-related hepatocellular carcinoma (HCC) and portal vein invasion. Emerging evidence suggests that the combination of localized regional therapy, multikinase inhibitors (MKIs), and immune checkpoint inhibitors (ICIs) yields promising outcomes for advanced HCC. ICIs not only effectively control HCC progression but may also facilitate a HBsAg clearance for hepatitis B-associated HCC patients, characterized by sustained HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid)and HBsAg clearance. This report details a case of hepatitis B cirrhosis with multifocal intrahepatic HCC and portal vein involvement, where the patient achieved complete response (CR) and HBsAg clearance following treatment with lenvatinib (an MKI), tislelizumab (a PD-1 inhibitor), and localized regional therapy. Case summary: A 61-year-old male with hepatitis B-related cirrhosis and advanced HCC with portal vein involvement underwent drug-loaded microsphere hepatic arterial chemoembolization (DEB-TACE) treatment. Additionally, the patient received a combination therapy of lenvatinib and tislelizumab. Following three DEB-TACE sessions, six months of lenvatinib, and seven cycles of tislelizumab, the patient attained CR and achieved HBsAg clearance of hepatitis B, as evidenced by the sustained absence of HBV DNA and HBsAg. Conclusion: The concurrent administration of DEB-TACE, lenvatinib, and tislelizumab demonstrated efficacy in achieving a HBsAg clearance for hepatitis B in a patient presenting with advanced HCC and portal vein tumor thrombosis. These findings suggest that a localized regimen incorporating MKIs and ICIs holds promise as a therapeutic approach for select cases of HBV-HCC, potentially leading to a HBsAg clearance of hepatitis B. Large-scale studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.